HAEGARDA reduced hae attacks by 95%*

Primary endpointOverall reduction in HAE attacks per month relative to placebo

Median Number of HAE Attacks/Month

95% reduction in HAE attacks with HAEGARDA 60 IU/kg vs placebo (median)

Study Design A 32-week crossover study with patients ≥12 years of age with symptomatic type 1 or 2 HAE (N=90).1

Least Squares (LS) Mean Analysis The mean reduction in number of HAE attacks per month with HAEGARDA 60 IU/kg vs placebo was 84%: 0.5 (95% CI 0.0–1.0) vs 4.0 (95% CI 3.5–4.6), respectively; P<0.001.

The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times2

*Median reduction in number of attacks with HAEGARDA vs placebo.

Taking haegarda reduced the use of rescue medication by >99%†1

Secondary endpoint Number of uses of rescue medication per month relative to placebo

99% less rescue medication with HAEGARDA 60 IU/kg vs placebo (median)
  • The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times2

Secondary endpoint High rate of response1

  • 90% of patients experienced ≥50% reduction in attacks relative to placebo

Least Squares (LS) Mean Analysis The mean reduction in number of rescue medication uses/month with HAEGARDA 60 IU/kg vs placebo was 89%.1

Median reduction in rescue medication use vs placebo.

You are now leaving the current website.